title: Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom.
abstract: Patient counseling is an important aspect of family planning. Patient choice, compliance, and satisfaction with a contraceptive method depend heavily on the counseling experience. This is especially true in the United Kingdom where contraceptives are provided to patients at no direct cost to them. Women are therefore more likely to choose a contraceptive option based on perceived desirability as opposed to cost. We surveyed physicians from six family planning centers in the United Kingdom who have extensive experience with levonorgestrel contraceptive implants with respect to counseling issues and patient acceptability of levonorgestrel implants. The physicians reported on their experience with 521 women. They acknowledged the need for and importance of counseling, and these centers provided preinsertion counseling 100% of the time. Primary responsibility for counseling was handled by the physician who spent, on average, 19 minutes per patient discussing the advantages and risks of levonorgestrel implants. Physicians felt that the majority of women (82%) accepting levonorgestrel implants had a positive experience. The incidence of bleeding irregularities was consistent with that reported in clinical trials, and this did not substantially affect the postinsertion acceptability of the product. Effective counseling is no doubt responsible for the high level of patient acceptance of these side effects. In a review of the literature, we found counseling to be a significant factor in a woman's tolerance of contraceptive-induced bleeding irregularities, which are frequently experienced with levonorgestrel implants. The results of our survey support the literature findings.
authors.affiliation: Family Planning & Well Woman Services, Edinburgh, United Kingdom.
authors.forename: J E
authors.initials: JE
authors.lastname: Davie
authors.forename: M R
authors.initials: MR
authors.lastname: Walling
authors.forename: D J
authors.initials: DJ
authors.lastname: Mansour
authors.forename: D
authors.initials: D
authors.lastname: Bromham
authors.forename: M
authors.initials: M
authors.lastname: Kishen
authors.forename: P
authors.initials: P
authors.lastname: Fowler
mesh_terms: D000293:Adolescent; D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage* / Q000009:adverse effects; D004343:Drug Implants; D005193:Family Planning Services; D005260:Female; D006801:Humans; D016912:Levonorgestrel / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D010342:Patient Acceptance of Health Care; D045167:Progesterone Congeners / Q000008:administration & dosage* / Q000009:adverse effects; D006113:United Kingdom
chemical_list: D003271:Contraceptive Agents, Female; D004343:Drug Implants; D045167:Progesterone Congeners; D016912:Levonorgestrel